...
首页> 外文期刊>Science Advances >Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo
【24h】

Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo

机译:使用离体信号网络反应的高内涵单细胞筛选发现精神疾病的药物

获取原文
           

摘要

There is a paucity of efficacious new compounds to treat neuropsychiatric disorders. We present a novel approach to neuropsychiatric drug discovery based on high-content characterization of druggable signaling network responses at the single-cell level in patient-derived lymphocytes ex vivo. Primary T lymphocytes showed functional responses encompassing neuropsychiatric medications and central nervous system ligands at established (e.g., GSK-3β) and emerging (e.g., CrkL) drug targets. Clinical application of the platform to schizophrenia patients over the course of antipsychotic treatment revealed therapeutic targets within the phospholipase Cγ1–calcium signaling pathway. Compound library screening against the target phenotype identified subsets of L-type calcium channel blockers and corticosteroids as novel therapeutically relevant drug classes with corresponding activity in neuronal cells. The screening results were validated by predicting in vivo efficacy in an independent schizophrenia cohort. The approach has the potential to discern new drug targets and accelerate drug discovery and personalized medicine for neuropsychiatric conditions.
机译:缺乏有效的新化合物来治疗神经精神疾病。我们提出了一种新的方法,用于神经精神科药物的发现,基于在患者来源的淋巴细胞中单细胞水平上可药物信号网络反应的高含量表征。原发性T淋巴细胞在既定(例如GSK-3β)和新兴(例如CrkL)药物靶点上均表现出功能性反应,包括神经精神科药物和中枢神经系统配体。在抗精神病治疗过程中该平台在精神分裂症患者中的临床应用表明,磷脂酶Cγ1–钙信号通路内具有治疗靶点。针对目标表型的化合物文库筛选将L型钙通道阻滞剂和皮质类固醇的子集确定为新型治疗相关药物类别,在神经元细胞中具有相应活性。通过预测独立精神分裂症队列中的体内疗效来验证筛选结果。该方法具有识别新的药物靶标并加速针对神经精神疾病的药物发现和个性化药物的潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号